Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Events / Regulatory / Schall Law Investigates TriSalus...
Regulatory securities fraud investigation

Schall Law Investigates TriSalus Life Sciences

Analysis based on 17 articles · First reported Jun 02, 2026 · Last updated Jun 10, 2026

Sentiment
-50
Attention
3
Articles
17
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The investigation into Caris Life Sciences for securities fraud is likely to negatively impact its stock price and investor confidence. The company's reduced revenue guidance and delayed product clearance from the United States — Food and Drug Administration further contribute to a bearish outlook for Caris Life Sciences.

Biotechnology Legal Services
Event Summary

The The Schall Law Firm has announced an investigation into Caris Life Sciences for potential violations of securities laws. This follows Caris Life Sciences' Q1 financial results reported on May 12, 2026, which showed a year-over-year revenue decline of over 2.9%. The company also reduced its full-year revenue guidance, citing lower Q1 revenues from commercial expansion and a significant delay in United States — Food and Drug Administration clearance for its TriNav Advance product, which is now approximately five months past its review goal. The The Schall Law Firm is encouraging shareholders who have suffered losses to participate in the investigation.

Key Actions
100 The Schall Law Firm announced investigation Caris Life Sciences
100 Pomerantz LLP investigating claims Caris Life Sciences
92 Caris Life Sciences reported Q1 results
85 Caris Life Sciences delayed FDA clearance United States — Food and Drug Administration
Entities Involved
priv
Caris Life Sciences
Caris Life Sciences is under investigation for allegedly issuing false and/or misleading statements and failing to disclose pertinent information to investors, leading to a decline in its stock price and a cut in revenue guidance.
Importance 100 Sentiment -70
priv
The Schall Law Firm
The The Schall Law Firm is initiating an investigation into Caris Life Sciences on behalf of its investors, seeking to represent shareholders who suffered losses.
Importance 80 Sentiment 20
priv
Pomerantz LLP
Pomerantz LLP is initiating an investigation into Caris Life Sciences Inc. on behalf of its investors, potentially leading to a class action lawsuit.
Importance 80 Sentiment 50
per
Brian Schall
Brian Schall is the contact person at the The Schall Law Firm for investors interested in participating in the investigation against Caris Life Sciences.
Importance 60 Sentiment 10
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration's delayed clearance for TriNav Advance is cited by Caris Life Sciences as a reason for its reduced revenue guidance.
Importance 40 Sentiment 0
per
Danielle Peyton
Danielle Peyton is the contact person at Pomerantz LLP for investors interested in joining the investigation against Caris Life Sciences Inc.
Importance 30 Sentiment 0
index
Nasdaq-100
Nasdaq-100 is the stock exchange where Caris Life Sciences Inc. is publicly traded, and its stock price decline was observed on this exchange.
Importance 10 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.